Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Peripheral × Observation × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Prostatic Neoplasms 18 Carcinoma, Non-Small-Cell Lung 17 Neoplasms 16 Colorectal Neoplasms 14 Endometrial Neoplasms 13 Stomach Neoplasms 12 Lung Neoplasms 11 Pancreatic Neoplasms 9 Leukemia, Myeloid, Acute 7 Colonic Neoplasms 7 Carcinoma, Hepatocellular 7 Oropharyngeal Neoplasms 6 Neoplasm Metastasis 6 Multiple Myeloma 6 Lymphoma, Large B-Cell, Diffuse 6 Esophageal Neoplasms 6 Sarcoma 5 Rectal Neoplasms 5 Mouth Neoplasms 5 Melanoma 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Head and Neck Neoplasms 4 Colorectal Neoplasms, Hereditary Nonpolyposis 4 Brain Neoplasms 4 Anus Neoplasms 4 Urinary Bladder Neoplasms 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Cyclophosphamide 38 Prednisone 29 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 26 Vincristine 24 Doxorubicin 24 romidepsin 19 Etoposide 19 Gemcitabine 17 10-propargyl-10-deazaaminopterin 15 fludarabine phosphate 14 Whole-Body Irradiation 13 Lenalidomide 13 Azacitidine 13 Peripheral Blood Stem Cell Transplantation 12 Mycophenolic Acid 11 Brentuximab Vedotin 11 Dexamethasone 10 Bortezomib 10 Cyclosporine 9 Alemtuzumab 8 fludarabine 7 Rituximab 7 belinostat 6 Cytarabine 6 Methotrexate 5 Granulocyte Colony-Stimulating Factor 5 Bendamustine Hydrochloride 5 selinexor 4 mogamulizumab 4 liposomal doxorubicin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07353840 2026-01-20

T-START-CR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon ⚡